Celularity Inc 2Q 2026: Revenue $5.43M, EPS $0.02— 10-Q Summary
Celularity Inc reported 2Q 2026 revenue of $5.43M, down 5.3% YoY, and net income of $0.55M, a turnaround from a $24.52M loss in 2Q 2025. Diluted EPS was $0.02, improved from ($1.02) YoY. Revenue mix shifted to product sales, while license/royalty revenue declined. The company completed the sale of NexGel biomaterials and focused on core cellular therapy programs.
How this was made
The 30-second read
Why it matters
The earnings surprise could trigger a brief rally in CELU, but the limited market depth may constrain sustained moves.
Market read
Micro‑cap earnings with a profit turnaround; modest trading interest expected.
What to watch
Potential future cash‑burn if R&D spending accelerates; reliance on a single product mix shift.
Background
Celularity Inc is a micro‑cap biotech focused on placenta‑derived cell therapies. The Q2 2026 filing shows a shift toward product sales and a reduction in license/royalty revenue.
Ticker impact
Celularity Inc reported Q2 2026 revenue of $5.43M and a net profit of $0.55M, turning a loss from the prior year into earnings.
potential upward pressure as the market prices in the profit turnaround
The surprise profit and revenue beat are fresh disclosures; however, the absolute size is modest, limiting broader market impact.
Market effects
May provide modest confidence for the cell‑therapy sector, but impact is limited to micro‑cap space.
U.S. biotech micro‑caps could see slight uptick.
Low; the news is company‑specific.
Counterpoint
Given the small scale, the profit swing may be quickly priced out, limiting upside.
Key entities
- companyCelularity Inc
US‑listed biotech (NASDAQ: CELU) reporting Q2 2026 results.
